Overall, the mOS in this particular population is quite impressive (49.5 months), suggesting that the prognosis in patients with brain metastases and ALK-positive NSCLC should be completely revised compared to wild-type population [73, 74]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.